Voices on EUP OHAMR

What are your expectations for the new partnership and what should it accomplish? What are the most important priorities in AMR research? Hear the voices of Dame Sally Davies, Irene Norstedt, Jan-Ingvar Jönsson, Till Bachmann and Sabiha Essack on the EUP OHAMR.

At the JPIAMR Final Conference, that took place on 7-8 May in Stockholm, Sweden, we asked Jan-Ingvar Jönsson, Chair of JPIAMR, and Till Bachmann and Sabiha Essack from the JPIAMR Scientific Advisory Board to share some key achievements of JPIAMR and their wishes and expectations for the new partnership.

We also met with Prof. Dame Sally Davies, Special Envoy on AMR for the UK, and Irene Norstedt, Director, DG Research and Innovation, European Commission, to hear their thoughts on AMR research prioritisation, existing knowledge gaps in the AMR field and the importance of One Health and international collaboration in the EUP OHAMR.

Watch the interviews through the link below!

open_in_new

Interviews from the JPIAMR Final Conference (youtube.com/jpiamr)

Link to another website

Watch the interviews with Jan-Ingvar Jönsson, Till Bachmann, Sabiha Essack, Irene Norstedt and Dame Sally Davies.

open_in_new

JPIAMR Final Conference 7-8 May 2025

Link to another website

Learn more about the conference that highlighted the impact of 10 years transnational AMR research and marked the the milestone of the JPIAMR transitioning to EUP OHAMR.

Research & Innovation call 2025

The first EUP OHAMR joint transnational call will be within the focus area of providing innovative and cost-effective treatment options. The call will be launched in November 2025.

The potential research objectives for this call will be as outlined in the EUP OHAMR Strategic Research and Innovation Agenda:

• To develop new antimicrobials, novel treatment protocols or alternative treatment strategies against Human Infectious diseases along with their respective diagnostics.
• To improve, preserve and reinforce the clinical efficacy of the current treatment antimicrobials.
• Identification of barriers to access, availability, quality and uptake of therapeutic solutions and development of solutions to overcome those barriers.
• Assessment and prediction of the impact of economic incentives and regulations on drug development, drug production, drug supply and treatment availability.

Welcome to EUP OHAMR!

After years of preparations, The European Partnership on One Health Antimicrobial Resistance has now started.

The partnership brings together 53 organisations across 30 countries from EU and beyond that together with the European Commission will provide joint support to boost One Health AMR Research and Innovation (R&I) in all its dimensions: coordinating joint transnational calls, actions to strengthen the capacity of the AMR research community, provide frameworks for alignment of policy and stakeholder engagement, and tools to valorise the new knowledge for the benefit of citizens and society as a whole.

Shahida Syed, Head of EUP OHAMR Secretariat:

“It is truly exciting that EUP OHAMR has begun! Through this partnership, we are fostering cross-sector research collaborations to drive the innovation needed for real-world impact. Together, we can find the instruments to understand and curb antimicrobial resistance on a global scale and develop and sustain life-saving treatments and tools.”

arrow_right_alt

Learn more about the partnership